The EU opened a formal antitrust investigation into Amazon on Wednesday centered on how the e-commerce giant uses merchants' data.Technologyread more
Investors are keen to find out how looming interest rate cuts will impact the second biggest U.S. lender by assets.Financeread more
Turo is a peer-to-peer car-sharing firm that is often referred to as the Airbnb for cars.Technologyread more
Mortgage interest rates surged last week to their highest level in a month, and consequently homebuyers turned on their heels.Real Estateread more
One semiconductor stock has soared above the rest since spring, and one of its biggest cheerleaders sees a larger breakout ahead.Trading Nationread more
U.S. officials see the deal as a threat to NATO, for which Turkey provides the second-largest military.World Politicsread more
Google's services have been blocked in China for several years, but the company still has a business there, as the tech giant seeks to sell products to Chinese firms in...Technologyread more
China may have signaled it's going more hard-line on trade, but it could be a good thing, former U.S. negotiator Clete Willems told CNBC.World Economyread more
Support for U.S. President Donald Trump increased slightly among Republicans after he lashed out on Twitter over the weekend in a racially charged attack on four minority...Politicsread more
A key read on the industry, the Architecture Billings Index, fell into negative territory in June, according to the American Institute for Architects. Inquiries for new...Real Estateread more
While the vote served as a show of solidarity for Democrats, it recommended no substantive penalty against Trump.Politicsread more
Pfizer will pay Medivation shareholders $81.50 per share in cash, a 21 percent premium to Medivation's closing stock price Friday of $67.16.
Ian Read, chairman and CEO of Pfizer, said in a joint press release the proposed deal is expected to "immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer. "
"The addition of Medivation will strengthen Pfizer's Innovative Health business and accelerate its pathway to a leadership position in oncology, one of our key focus areas," he said, "which we believe will drive greater growth and scale of that business over the long-term. This transaction is another example of how we are effectively deploying our capital to generate attractive returns and create shareholder value."
Pfizer will get access to Medivation's prostate cancer drug Xtandi, which the companies said treated 64,000 men to date in the U.S. alone and generated about $2.2 billion in worldwide net sales over the past four quarters.
Medivation has two development-stage drugs: breast cancer drug talazoparib and lymphoma drug pidilizumab. This will also add to Pfizer's oncology portfolio. Cancer remains the second leading cause of death in the U.S., according to the Center for Disease Control and Prevention.
Pfizer said the acquisition would also add about 5 cents to earnings in the first full year after close and doesn't expect the deal to impact its 2016 forecast.
Both company's boards have unanimously approved the merger.
Pfizer said it expects to complete the acquisition in the third or fourth quarter.
Medivation's stock has risen significantly this year, up more than 66 percent.
MDVN 2016 Chart
Shares of Pfizer dropped to nearly 1 percent Monday in premarket trading. The company's stock has gone up this year, up more than 8 percent.
PFE 2016 Chart